Impressions: 1840
In 2022, the pandemic continued to bring in a windfall for
pharmaceutical companies manufacturing Covid-19 products, with Pfizer’s total annual sales reaching
a record high by surpassing US$ 100 billion for the first time.AbbVie, despite not ...
Impressions: 1546
Since 2022, layoffs have become commonplace. The ongoing global banking crisis, coupled with pre-existing factors such as the Ukraine-Russia conflict, inflation, looming recession and rising interest rates have made the business environment even more...
Impressions: 2162
The Covid-19 pandemic expedited the
growth of contract development and manufacturing organizations (CDMOs) as
pharma companies increasingly turned to them to accelerate drug development.
However, by the end of 2022, a decline in demand for
Covid ...
Impressions: 1917
Over the last five years, a
lot has changed for Pfizer Inc, one of the world’s leading pharmaceutical companies based on pharma sales revenue. From entering into an agreement with German biotechnology company BioNTech SE in August 2018 fo...
Impressions: 1626
Endocrinology, a medicinal
branch that deals with endocrine and metabolic disorders, is witnessing
cutting-edge drug research to develop advanced drugs that can treat
diabetes, obesity, hypoparathyroidism and other
disorders.The endocrinology mar...
Impressions: 2035
The pandemic years haven’t been great for dealmaking. Our analysis of top 10 biopharma M&A transactions shows that after a blockbuster 2019, when the combined value of top 10 biopharma M&A transactions had hit US$ 207 billion, M&A activity decr...
Impressions: 1148
India’s US$ 49 billion pharmaceutical industry has often been described as the ‘pharmacy to the world’, as it is the world’s largest exporter of generic drugs. But the country is having to contend with one scandal after a...
Impressions: 1690
In 2022, the world finally began to emerge out of Covid-related
restrictions. Though 2020 and 2021 saw several travel-related curbs, there was
no let up in the speed at which generic active pharmaceutical ingredient (API)
manufacturers were submit...
Impressions: 1289
This week, AbbVie’s Humira (adalimumab) saw its 20-year exclusive
run come to an end in the United States as Amgen launched its copycat — Amjevita. This is just the start of
the onslaught of Humira copycats, as seven other biosimil...
Impressions: 1812
The year 2022 saw the lowest number of drug approvals by the US Food and Drug
Administration (FDA) since 2016. The agency’s Center for Drug Evaluation
and Research (CDER) approved only 37 new drugs, a decrease of 26
percent from the 50 ...